Evidence map›Paper›PMID 41617084›Full record

ArticleVirologica Sinica2026

Characteristics of humoral and T-cell immune responses in people living with HIV after breakthrough SARS-CoV-2 Omicron variant infection during December 2022 to January 2023.

Hai-Bo Ding, Hong Sun, Yong-Hui Feng, Qing-Hai Hu, Qi Wang, Nan Li, Qing-Qing Ma, Wen Tian, Yan-Chun Peng, Jia-Qi Chen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hai-Bo DingState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Hong SunState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China; Chinese Academy of Medical Sciences Oxford Institute, Old Road Campus, Oxford OX3 7BN, UK.
Yong-Hui FengState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Qing-Hai HuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Qi WangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Nan LiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Qing-Qing MaState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Wen TianState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Yan-Chun PengChinese Academy of Medical Sciences Oxford Institute, Old Road Campus, Oxford OX3 7BN, UK; MRC Weatherall Institute of Molecular Medicine University of Oxford John Radcliffe Hospital, Headington Oxford OX3 9DS, UK.
Jia-Qi ChenState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Jin-Li SongState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Hua-Lu CuiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Hai-Long LiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Wen-Qing GengState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China.
Tao DongChinese Academy of Medical Sciences Oxford Institute, Old Road Campus, Oxford OX3 7BN, UK; MRC Weatherall Institute of Molecular Medicine University of Oxford John Radcliffe Hospital, Headington Oxford OX3 9DS, UK. Electronic address: tao.dong@ndm.ox.ac.uk.
Xiao-Xu HanState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China. Electronic address: hanxiaoxu@cmu.edu.cn.
Hong ShangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, NHC Key Laboratory of AIDS Prevention and Treatment, National Clinical Research Center for Laboratory Medicine, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China; Key Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang 110001, China; Key Laboratory of AIDS Immunology of Liaoning Province, Shenyang 110001, China. Electronic address: hongshang100@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to inherent immune deficiency, the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immune responses in people living with HIV (PLWH) following breakthrough infection with remain incompletely elucidated. A large-sample real-world study was conducted from December 2022 to January 2023, which systematically analyzed immune responses in 1367 PLWH and 219 people without HIV (PWOH) by evaluating serum IgG antibody levels against SARS-CoV-2 wild-type strain and Omicron variants, neutralizing antibody titers, as well as the features of SARS-CoV-2-specific T-cell responses in this population. The results demonstrated that the breakthrough Omicron infection rate in PLWH (60.6%) was significantly lower than that in PWOH. Meanwhile, PLWH exhibited notably reduced IgG antibody levels against both the wild-type strain and Omicron BF.7 variant, with a concurrent decline in neutralizing antibody titers. However, fully vaccinated PLWH with CD4

Indexed as

COVID-19HIV InfectionsImmunity, CellularImmunity, HumoralSARS-CoV-2T-LymphocytesAdultAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsCD4 Lymphocyte CountCOVID-19 VaccinesFemaleHumansImmunoglobulin GMaleAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GAntibody levelsHuman immunodeficiency virus (HIV)Immune responseOmicronSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)T-cell response

Identifiers

PMID41617084
PMCPMC13007309

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.